

# Impact of Microstructural Properties on Drug Release from PLGA Microspheres

Ruifeng Wang<sup>1</sup>, Andrew G. Clark<sup>2</sup>, Quanying Bao<sup>1</sup>, Yan Wang<sup>3</sup>, Bin Qin<sup>3</sup>, Shawn Zhang<sup>2</sup>, Diane J. Burgess<sup>1</sup>

<sup>1</sup> University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA


<sup>2</sup> DigiM Solution LLC, 500 West Cummings Park, Suite 3650, Woburn, MA 01801, USA

<sup>3</sup> Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA

Contact Information: [ruifeng.2.wang@uconn.edu](mailto:ruifeng.2.wang@uconn.edu); [d.burgess@uconn.edu](mailto:d.burgess@uconn.edu)

## Introduction

- In the development of complex generic products such as poly (lactic-co-glycolic acid) (PLGA)-based microspheres, qualitative (Q1) and quantitative (Q2) sameness may not be sufficient to achieve comparable product performance as formulation characteristics are manufacturing dependent. This warrants special attention on similarity in microstructure (Q3).
- The Q3 properties can affect drug release and consequently, the efficacy and safety. The objective of this work was to investigate the relationship between microstructure and the release characteristics of microspheres using focused ion beam scanning electron microscopy (FIB-SEM) and quantitative artificial intelligence (AI)-based image analytics.





### Microstructure properties of material phases (polymer, drug, and pore):

- Volume fraction
- Size distribution
- Spatial distribution

## Methods

### Formulation process of minocycline hydrochloride microspheres




## Results

### Physicochemical properties of the prepared microspheres


Table 1. Drug loading and size of minocycline hydrochloride microspheres prepared with different processing parameters. All data are presented as mean  $\pm$  SD (n=3).

Stirring rate (rpm)	Silicone oil viscosity (cSt)	Drug Loading (% w/w)	Particle Size (D <sub>50</sub> , Volume, $\mu$ m)	Particle Size (D <sub>50</sub> , Number, $\mu$ m)
FA	350	26.18 $\pm$ 0.31	74.01 $\pm$ 1.81	56.10 $\pm$ 0.43
FB	350	26.17 $\pm$ 0.14	62.34 $\pm$ 0.39	48.03 $\pm$ 0.18
FC	600	26.37 $\pm$ 0.27	72.47 $\pm$ 0.81	54.12 $\pm$ 0.16
FD	600	26.41 $\pm$ 0.47	57.56 $\pm$ 0.40	41.43 $\pm$ 0.36

### In vitro release characteristics




- In vitro release profiles of the prepared microspheres using the sample-and-separate method. All data are presented as mean  $\pm$  SD (n=3). The release profiles were analyzed using the first order model.




### Correlation


Polymer ratio (%) in 35% outer layer	k <sub>1</sub>
FA	53.42
FB	49.49
FC	61.90
FD	51.82



### In vitro degradation



- SEM cross-sectional images of the prepared microsphere formulations incubated in release medium at day 6. The green arrows point to the remaining drug particles inside the microspheres. The ratio of R<sub>1</sub>/R<sub>2</sub> is 35%.



## Conclusions

- Microstructural properties (e.g., volume fraction and spatial distribution of polymer, drug, and pores) of four in-house microsphere formulations were determined using FIB-SEM.
- Internal phase fractions and phase spatial distributions were identified that related to the release performance. The release rate was correlated with the polymer content in the outer layer.
- The established correlation between microstructural properties and release characteristics can potentially support a more robust understanding of the impact of the microstructure properties on the release mechanisms of microspheres, and facilitate the establishment of Q3 equivalence of two products.

## References

Ruifeng, W., Quanying, B., Andrew G., et al. *Int. J. of Pharm.* 628, 122292.  
Andrew G., C., Ruifeng, W., Yuri, Q., et al. *J. Control. Release.* 349, 580-591.  
Jie, S., & Diane J., B. *J. Pharm. Pharmacol.* 64(7), 986-996.

## Acknowledgments and Disclaimer

- Funding for this project was provided by the U.S. Food and Drug Administration through the Contract #75F40119C10157. The content reflects the views of the authors and should not be construed to represent FDA's views or policies.

UCONN  
SCHOOL OF PHARMACY

DigiM  
FDA